Combination of tebotelimab with margetuximab
The anti-HER2 therapeutic mAb margetuximab has been engineered for enhanced affinity for the activating FcγRIIIA (CD16A) and reduced affinity for the inhibitory FcγRIIIB (CD32B) relative to the non-Fc-engineered parental anti-HER2 mAb trastuzumabThis evidence supported rationale for exploring the safety and preliminary clinical utility of tebotelimab in combination with margetuximab in patients with HER2